The relation of fibrosis stage with nutritional deficiencies and bioelectrical impedance analysis of body composition in patients with chronic hepatitis C
Journal Title: Annals of Hepatology - Year 2016, Vol 15, Issue 4
Abstract
Background. Nutritional deficiencies may aggravate the course of chronic hepatitis C (CHC). Our aim has been to perform a comprehensive analysis of body composition and nutritional deficiencies in CHC patients in non-cirrhotic and compensated cirrhotic stages to correlate the detected deficiencies with the fibrosis stage. Material and methods. Body multifrequency bioimpedance analysis (BIA) and a wide and simultaneous analytical profile were prospectively performed in 74 CHC patients (36 male) with known METAVIR fibrosis stage established with liver biopsy or transient elastography. Results were analyzed to identify deviations from the normal range and variations according to the fibrosis stage. Results. Body fat compartment was greater in women. Body composition did not change among the 4 stages of liver fibrosis. Low levels (< 30 μg/L) of vitamin D were detected in 74.3% of patients irrespective of the fibrosis stage. Most analytical results remained into the normal range with the exceptions of thrombocytopenia and vitamin A deficiency, that were limited to the stage 4 of fibrosis, and low Zn and LDL-cholesterol values, that were frequently found in patients with advanced (F3 and F4) fibrosis stage. Conclusion. Body composition and most biochemical parameters, including cyanocobalamin, folic acid and vitamin E, are well preserved in compensated patients with CHC, with the exception of generalized vitamin D insufficiency and of deficiencies of vitamin A and zinc that are restricted to the more advanced, although still compensated, stages of the disease.
Authors and Affiliations
Beatriz Mateos-Muñoz, María Devesa-Medina, Avelina Suárez, Angélica Larrad-Sáinz, Enrique Rey-Díaz-Rubio, Luis Ortega-Medina, José Ladero
Keywords
Related Articles
- EP ID EP78593
- DOI 10.5604/16652681.1202905
- Views 157
- Downloads 0
Cefuroxime axetil-induced liver failure
Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials
Introduction & aim. Faldaprevir is a potent once-daily (q.d.) hepatitis C virus (HCV) NS3/4A protease inhibitor. The STARTVerso1and STARTVerso2 phase 3 studies evaluated faldaprevir plus peginterferon alfa-2...
Clinical characteristics of liver failure from a systemic cause: A report from an advanced critical care center
Background/Purpose. In Japan, acute liver failure (ALF) has generally been described using the diagnostic term, “fulminant hepatitis”, because of the fact that most cases of ALF has been thought to occur in association...
Treatment of recurrent genotype 4 hepatitis C after liver transplantation: early virological response is predictive of sustained virological response. An AISF RECOLT-C Group Study
Introduction. Hepatitis C virus genotype 4 is predominant in the Middle East and Northern Africa, even if it has recently spread to Southern Europe. Data about the treatment of post-liver transplantation (LT) genotype 4...
Gene expression profiling reveals key genes and pathways related to the development of non-alcoholic fatty liver disease
Background. This study aims to identify key genes and pathways involved in non-alcoholic fatty liver disease (NAFLD). Materialand methods. The dataset GSE48452 was downloaded from Gene Expression Omnibus, including 14 c...